Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MSH6
REST API REST API
Homo sapiens
MSH6 is differentially expressed in 347 experiments: 146 organism parts: testis, lung, ... (144 more);, 260 disease states: normal, cervical carcinoma, ... (258 more);, 113 cell types 407 cell lines 49 compound treatments and 88 other conditions.
Synonyms GTBP
Orthologs LOC100360342 (Rattus norvegicus)   E1BWV7_CHICK (Gallus gallus)   msh6 (Danio rerio)   E1B9Q4_BOVIN (Bos taurus)   MSH6 (Saccharomyces cerevisiae)   F6SHJ0_CIOIN (Ciona intestinalis)   Msh6 (Mus musculus)   Msh6 (Drosophila melanogaster)   msh6 (Xenopus laevis)   MSH6 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, reciprocal meiotic recombination, DNA binding, protein binding, DNA repair, nuclear chromatin, double-stranded DNA binding, damaged DNA binding, DNA damage response, signal transduction resulting in induction of apoptosis, ATPase activity, nuclear chromosome, MutSalpha complex, determination of adult lifespan, mismatched DNA binding, meiotic mismatch repair, ATP binding, magnesium ion binding, DNA-dependent ATPase activity, nucleus, mismatch repair, nucleotide binding, chromatin binding, four-way junction DNA binding, guanine/thymine mispair binding, MutLalpha complex binding, somatic recombination of immunoglobulin gene segments, ATP catabolic process, ADP binding, positive regulation of helicase activity, induction of apoptosis by intracellular signals, oxidized purine DNA binding, somatic hypermutation of immunoglobulin genes, negative regulation of DNA recombination, isotype switching, single guanine insertion binding, single thymine insertion binding
InterPro Term DNA_mismatch_repair_MutS_core, DNA_mismatch_repair_MutS_clamp, DNA_mismatch_repair_MutS-lik_N, DNA_mismatch_repair_MutS_connt, DNA_mismatch_repair_MutS_C, PWWP, DNA_mismatch_repair_Msh6
UniProt Accession C9J7Y7, P52701, C9J8Y8, Q1L838, C9JH55, B4DF41, E7ER38, F5H2F9, F5H769, F5H3S1, F8WAX8, F8W7G9
Gene-Disease Assocation ENDOMETRIAL CANCER, MISMATCH REPAIR CANCER SYNDROME, BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1; BROVCA1, MutS, E. COLI, HOMOLOG OF, 6; MSH6
Search EB-eye ENSG00000116062
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, E-MTAB-62, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
HepG2
2
E-GEOD-21154, E-MTAB-37
HL-60
2
E-GEOD-96, E-GEOD-5258
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
401 more value(s).


Cell type

studied in E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (53 experiments)

Factor Value U/D Experiments
adipocyte
2
E-AFMX-5, E-MTAB-25
1
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
centroblast
2
E-TABM-702, E-GEOD-15271
CD14+ monocyte
1
2
3
E-MEXP-1600, E-AFMX-5, E-TABM-145
107 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MTAB-62, E-MTAB-680, ... (70 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-96, E-GEOD-995, E-MTAB-62
prostate carcinoma
3
E-GEOD-96, E-MTAB-62, E-MTAB-37
lung adenocarcinoma
1
3
E-MEXP-231, E-MTAB-62, E-MTAB-37, E-GEOD-2514
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
lymphoma
2
E-MTAB-62, E-MTAB-37
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
254 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-5258, E-TABM-782, E-GEOD-5824, ... (29 experiments)

Factor Value U/D Experiments
none
4
9
E-GEOD-5824, E-GEOD-20719, E-MEXP-1601, E-TABM-868, E-GEOD-412, ... (13 experiments)
vanadium pentoxide
1
E-GEOD-5339
granulocyte-colony stimulating factor
1
E-GEOD-7400
ponasterone A
1
E-GEOD-3113
mannitol
1
E-GEOD-6400
HMB-PP (phosphoantigen)
1
E-MEXP-1601
43 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
81
2
1
E-GEOD-3494
81 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-22513, E-GEOD-19246, E-MEXP-1251, E-GEOD-21589, ... (13 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-1638, E-GEOD-20033, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-19665, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-2466, E-GEOD-18005, E-TABM-868, E-TABM-601, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-GEOD-20504, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321, E-MEXP-2177

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-4525, E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, ... (10 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, ... (7 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.473 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM